Description

Tirzepatide is a once-weekly injectable medication, FDA-approved under the brand name Mounjaro to treat type 2 diabetes and FDA-approved under the brand name Zepbound for weight loss. Tirzepatide is a dual-action GLP-1/GIP agonist that works by mimicking your body’s natural hormones, helping you feel fuller faster and for longer.

Mounjaro is a medication that is FDA-approved to improve blood sugar control in adults with type 2 diabetes. Recently, Zepbound received FDA approval for weight loss in adults with obesity (BMI≥30) or overweight (BMI≥27) with a weight-related condition. Both Mounjaro and Zepbound have the same active ingredient, tirzepatide, and are available in the same dose strengths.

Tirzepatide, including both Mounjaro (FDA-approved for treatment of type 2 diabetes) and Zepbound (FDA-approved for weight loss), is a glucagon-like peptide 1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) agonist. This means that tirzepatide acts like the GLP-1 and GIP hormones to lower blood sugar levels and decrease your appetite so you lose weight. It also slows down how fast food moves through your body, which may help you stay full for longer. Both Mounjaro and Zepbound are once-weekly medications administered via a single-use prefilled injection pen with the prescribed dose. You administer the injection under the skin of your stomach, thigh, or arm.